Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody

Am J Obstet Gynecol. 1989 Feb;160(2):439-43. doi: 10.1016/0002-9378(89)90468-7.


Effects of therapy, antibody titer, and pregnancy history on pregnancy outcome were evaluated in pregnancies of women with antiphospholipid antibody. Prior fetal death and a high antiphospholipid antibody titer (greater than 40 IgG phospholipid units) contributed independently, in an additive manner, to current fetal loss. Twenty-one pregnancies occurred in asymptomatic women who had both prior fetal death and a high IgG antiphospholipid antibody titer. In this very high-risk group, 9 of 11 (82%) of pregnancies treated with prednisone, 10 to 60 mg/day, ended in fetal death, compared with 5 of 10 (50%) not treated with prednisone (p approximately 0.01, life-table analysis). Of pregnancies treated with aspirin, 80 mg/day, 9 of 14 (64%) treated and 5 of 7 (71%) not treated with prednisone had a fetal death (difference not significant). Prednisone does not improve, and may worsen, current fetal outcome in asymptomatic pregnant women with a high antiphospholipid antibody titer and prior fetal death.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aspirin / therapeutic use
  • Autoantibodies / analysis*
  • Female
  • Fetal Death / prevention & control*
  • Humans
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / immunology
  • Phospholipids / immunology*
  • Prednisone / therapeutic use*
  • Pregnancy
  • Pregnancy Complications / drug therapy
  • Pregnancy Complications / immunology
  • Prospective Studies
  • Recurrence


  • Autoantibodies
  • Phospholipids
  • Aspirin
  • Prednisone